MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression.

ABSTRACT:

Aim

Immunotherapy and immune checkpoint inhibitors (ICI) have changed cancer care for many patients; however, breast cancers have exhibited minimal response to single agent ICI therapy. There is a significant need to identify novel targets capable of increasing cancer cell immunogenicity and response to ICIs in breast cancer. Mitogen activated protein kinase (MAPK) signaling is essential for many cellular processes but the relationship between MAPK signaling and cancer cell immunogenicity is less well understood. Recent reports suggest that MEK inhibition (MEKi) affects the tumor-immune microenvironment by altering the expression of interferon responsive PD-L1 and MHC-I through unknown mechanisms.

Methods

Using western blotting and flow cytometry, we sought to determine whet

SUBMITTER: Franklin DA 

PROVIDER: S-EPMC7556720 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature